Moderna named James Mock as its CFO Wednesday morning, months after the company’s previous CFO left following two days on the job.
Mock will begin in his new role on September 6. He replaces David Meline, who is retiring but will stay on as a consultant to aid in the transition process. Mock previously served as SVP and CFO of PerkinElmer, a life sciences and diagnostics company.
Moderna had named Jorge Gomez as CFO in mid-April. However, shortly after joining the company in May, Gomez left the company following disclosures from his previous employer, Dentsply Sirona, about an investigation into financial reporting. Dentsply Sirona subsequently received a written notice of filing delinquency from Nasdaq because it had not yet filed a Form 10-Q for the first quarter of 2022 due to the internal probe.
Despite the C-suite shakeups, Moderna continues to produce strong financial performances. In its latest earnings report, Moderna recorded total Q2 revenue of $4.7 billion, up from $4.4 billion in Q2 2021, due to increased sales of the company’s COVID-19 vaccine.
Additionally, the company’s net income reached nearly $6 billion, marking an increase of almost $2 billion year-over-year.
“I am thrilled to welcome Jamey to Moderna’s executive committee as our chief financial officer,” Moderna CEO Stéphane Bancel said in a statement. “Moderna is at an exciting stage with a growing mRNA platform, including four Phase 3 trials occurring this year and upcoming proof-of-concept data in rare diseases and immuno-oncology, significant commercial momentum and a strong financial position.”
